ID   PER-909
AC   CVCL_C9CN
SY   P896-CL
DR   Wikidata; Q123033267
RX   PubMed=26551281;
RX   PubMed=29348827;
CC   Sequence variation: Gene fusion; HGNC; HGNC:13575; BRD4 + HGNC; HGNC:29919; NUTM1; Name(s)=BRD4-NUTM1, BRD4-NUT; Note=BRD4 exon 15 fused to NUTM1 exon 2 (PubMed=26551281).
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Transcriptomics; RNAseq.
CC   Derived from site: In situ; Nose, nasal cavity; UBERON=UBERON_0001707.
DI   NCIt; C45716; NUT carcinoma
DI   ORDO; Orphanet_443167; NUT midline carcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_C9CP ! PER-904N
SX   Female
AG   14Y
CA   Cancer cell line
DT   Created: 05-10-23; Last updated: 10-04-25; Version: 4
//
RX   PubMed=26551281; DOI=10.1038/oncsis.2015.33; PMCID=PMC4670959;
RA   Stirnweiss A., McCarthy K., Oommen J., Crook M.L., Hardy K.,
RA   Kees U.R., Wilton S.D., Anazodo A.C., Beesley A.H.;
RT   "A novel BRD4-NUT fusion in an undifferentiated sinonasal tumor
RT   highlights alternative splicing as a contributing oncogenic factor in
RT   NUT midline carcinoma.";
RL   Oncogenesis 4:e174.1-e174.5(2015).
//
RX   PubMed=29348827; DOI=10.18632/oncotarget.22862; PMCID=PMC5762512;
RA   Stirnweiss A., Oommen J., Kotecha R.S., Kees U.R., Beesley A.H.;
RT   "Molecular-genetic profiling and high-throughput in vitro drug
RT   screening in NUT midline carcinoma-an aggressive and fatal disease.";
RL   Oncotarget 8:112313-112329(2017).
//